Journal
Annals of Clinical and Translational Neurology
Publication Date
10-1-2023
Volume
10
Issue
10
First Page
1738
Last Page
1748
Document Type
Open Access Publication
DOI
10.1002/acn3.51863
Rights and Permissions
Monane, M., Johnson, K.G., Snider, B.J., Turner, R.S., Drake, J.D., Maraganore, D.M., Bicksel, J.L., Jacobs, D.H., Ortega, J.L., Henderson, J., Jiang, Y., Huang, S., Coppinger, J., Fogelman, I., West, T. and Braunstein, J.B. (2023), A blood biomarker test for brain amyloid impacts the clinical evaluation of cognitive impairment. Ann Clin Transl Neurol, 10: 1738-1748. https://doi.org/10.1002/acn3.51863 © 2023 C2N Diagnostics and The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Recommended Citation
Monane, Mark; Snider, B Joy; and et al., "A blood biomarker test for brain amyloid impacts the clinical evaluation of cognitive impairment." Annals of Clinical and Translational Neurology. 10, 10. 1738 - 1748. (2023).
https://digitalcommons.wustl.edu/oa_4/2984
Department
ICTS (Institute of Clinical and Translational Sciences)
